Cingulate ticker
WebSep 10, 2024 · Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder ... WebApr 4, 2024 · The Phase 3 CTx-1301-022 study ( NCT05631626) is assessing the onset and duration of CTx-1301 in up to 25 adults (age range: 18-55 years) with ADHD in an adult laboratory classroom setting. The ...
Cingulate ticker
Did you know?
WebOct 4, 2024 · IPO details. Cingulate Inc. is slated to go public on Thursday, October 7. The company will begin trading on NASDAQ under the ticker symbol CING. It will offer 4.6 … WebDec 15, 2024 · The current estimated net worth of Cingulate Inc's Director, Peter Werth, is estimated to be about $1.33M . Peter Werth owns about 997,014 units of Cingulate Inc …
WebDec 10, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … WebApr 10, 2024 · Company Description. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of …
WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company profile for Cingulate Inc. (CING) including business summary, … Discover historical prices for CING stock on Yahoo Finance. View daily, weekly or … Find the latest Cingulate Inc. (CING) stock discussion in Yahoo Finance's forum. … Get the detailed quarterly/annual income statement for Cingulate Inc. (CING). … Find out all the key statistics for Cingulate Inc. (CING), including valuation … View the basic CING option chain and compare options of Cingulate Inc. on … Find out the direct holders, institutional holders and mutual fund holders for … See Cingulate Inc. (CING) Environment, Social and Governance Ratings to help … See Cingulate Inc. (CING) stock analyst estimates, including earnings and … Trial On Track for 3Q 2024 Results Pivotal Phase 3 Trial in Pediatric/Adolescent … WebApr 11, 2024 · A high-level overview of Cingulate Inc. (CING) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
WebJul 13, 2024 · Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity …
WebMar 10, 2024 · Debt. Other. Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services; director and officer insurance; and investor and … designing a flash separatorWebApr 8, 2024 · Open an account. Provide your personal information and sign up. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account. Search for the stock name – CING. Search for the stock by name or ticker symbol. Buy the stock. Place your order. chuck cope synchronized skating competitionWebDec 10, 2024 · The shares and warrants began trading on the Nasdaq Capital Market under the ticker symbols “CING” and “CINGW,” respectively, on December 8, 2024. ... chuck copeland griffin gaWebSep 10, 2024 · Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder ... designing a folded horn speaker enclosureWebMar 13, 2024 · Cingulate’s comprehensive agreement with Indegene covers most facets of the commercialization process, including sales, PRMA (pricing, reimbursement and market access), medical affairs, medical communications, pharmacovigilance, regulatory, marketing and commercial operations support. ... Börse aktuell - Live Ticker. Nach Fed-Protokoll: ... chuck corbett sioux cityWebDec 10, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next ... designing a flitch beamWebCING Complete Cingulate Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. designing a fitness room